Neuroprotective effects of riluzole in early phase Parkinson's disease on clinically relevant parameters in the marmoset MPTP model

Neuropharmacology

Volumn 62, Issue 4, 2012, Pages 1700-1707

  Verhave, Peternella S ^a,b   Jongsma, Marjan J ^a   Van Den Berg, Roland M ^a   Vanwersch, Raymond A P ^a   Smit, August B ^b   Philippens, Ingrid H C H M ^c  

^a TNO   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Behavior; Dopamine; Marmoset; MPTP; Parkinson's disease; Riluzole; Sleep

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; RILUZOLE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CALLITRICHINAE; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; EYE HAND COORDINATION; FEMALE; JUMPING; LOCOMOTION; MALE; MUSCLE TONE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REM SLEEP; SLEEP PARAMETERS; SUBSTANTIA NIGRA; SYMPTOMATOLOGY;

ANIMALS; CALLITHRIX; CORPUS STRIATUM; DOPAMINE; DOPAMINERGIC NEURONS; FEMALE; MALE; MPTP POISONING; NEUROPROTECTIVE AGENTS; RILUZOLE; SUBSTANTIA NIGRA;

EID: 84856458354     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.11.016     Document Type: Article

References (45)

1. T. Araki, T. Kumagai, K. Tanaka, M. Matsubara, H. Kato, Y. Itoyama, and Y. Imai Neuroprotective effect of riluzole in MPTP-treated mice Brain Res. 918 2001 176 181 (Pubitemid 33001503)
2. P. Barneoud, M. Mazadier, J.M. Miquet, S. Parmentier, P. Dubedat, A. Doble, and A. Boireau Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat Neuroscience 74 1996 971 983 (Pubitemid 26313341)
3. A. Benazzouz, T. Boraud, P. Dubedat, A. Boireau, J.M. Stutzmann, and C. Gross Riluzole prevents MPTP-induced parkinsonism in the rhesus monkey: a pilot study Eur. J. Pharmacol. 284 1995 299 307
4. G. Bensimon, L. Lacomblez, and V. Meininger A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group N. Engl. J. Med. 330 1994 585 591 (Pubitemid 24065791)
5. D. Berg Biomarkers for the early detection of Parkinson's and Alzheimer's disease Neurodegener. Dis. 5 2008 133 136 (Pubitemid 351347830)
6. A. Boireau, P. Dubedat, F. Bordier, A. Imperato, and S. Moussaoui The protective effect of riluzole in the MPTP model of Parkinson's disease in mice is not due to a decrease in MPP(+) accumulation Neuropharmacology 39 2000 1016 1020 (Pubitemid 30155708)
7. M.A. Burguillos, T. Deierborg, E. Kavanagh, A. Persson, N. Hajji, A. Garcia-Quintanilla, J. Cano, P. Brundin, E. Englund, J.L. Venero, and B. Joseph Caspase signalling controls microglia activation and neurotoxicity Nature 472 7343 2011 319 324
8. J.J. Cao, K.S. Li, and Y.Q. Shen Activated immune cells in Parkinson's disease J. Neuroimmune Pharmacol. 6 3 2011 323 329
9. D. Centonze, P. Calabresi, A. Pisani, S. Marinelli, G.A. Marfia, and G. Bernardi Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons Neuropharmacology 37 1998 1063 1070 (Pubitemid 28401495)
10. C.S. Chan, T.S. Gertler, and D.J. Surmeier Calcium homeostasis, selective vulnerability and Parkinson's disease Trends Neurosci. 32 2009 249 256
11. S.L. Cousins, M. Papadakis, A.R. Rutter, and F.A. Stephenson Differential interaction of NMDA receptor subtypes with the post-synaptic density-95 family of membrane associated guanylate kinase proteins J. Neurochem. 104 2008 903 913 (Pubitemid 351143653)
12. E. Diguet, P.O. Fernagut, C. Scherfler, G. Wenning, and F. Tison Effects of riluzole on combined MPTP + 3-nitropropionic acid-induced mild to moderate striatonigral degeneration in mice J. Neural Transm. 112 2005 613 631 (Pubitemid 40591195)
13. A. Doble The pharmacology and mechanism of action of riluzole Neurology 47 1996 S233 S241
14. J. Duda Is the initial insult in Parkinson's disease and dementia with lewy bodies a neuritic dystrophy? Ann NY Acad Sci 991 2003 295 297 (Pubitemid 36793826)
15. D.M. Edgar, W.C. Dement, and C.A. Fuller Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation J. Neurosci. 13 1993 1065 1079 (Pubitemid 23067594)
16. J.M. Fearnley, A.J. Lees, T. Revesz, D.J. Brooks, and R.S. Frackowiak Ageing and Parkinson's disease: substantia nigra regional selectivity Brain 114 Pt 5 1991 2283 2301
17. G. Fiskum, A. Starkov, B.M. Polster, and C. Chinopoulos Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease Ann. N. Y. Acad. Sci. 991 2003 111 119 (Pubitemid 36793807)
18. E. Fumagalli, P. Bigini, S. Barbera, M. De Paola, and T. Mennini Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease Exp. Neurol. 198 2006 114 128 (Pubitemid 43243750)
19. J.F. Gagnon, M.A. Bedard, M.L. Fantini, D. Petit, M. Panisset, S. Rompre, J. Carrier, and J. Montplaisir REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease Neurology 59 2002 585 589 (Pubitemid 34919994)
20. J.T. Greenamyre, G. MacKenzie, T.I. Peng, and S.E. Stephans Mitochondrial dysfunction in Parkinson's disease Biochem. Soc. Symp. 66 1999 85 97 (Pubitemid 129639025)
21. J.P. Hubert, J.C. Delumeau, J. Glowinski, J. Premont, and A. Doble Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action Br. J. Pharmacol. 113 1994 261 267 (Pubitemid 24271747)
22. M. Irifune, N. Kikuchi, T. Saida, T. Takarada, Y. Shimizu, C. Endo, K. Morita, T. Dohi, T. Sato, and M. Kawahara Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice Anesth. Analg. 104 2007 1415 1421 (Pubitemid 46791276)
23. J. Jankovic, and C. Hunter A double-blind, placebo-controlled and longitudinal study of riluzole early Parkinson's disease Parkinsonism Relat. Disord. 8 2002 271 276 (Pubitemid 34142206)
24. P. Jenner Functional models of Parkinson's disease: a valuable tool in the development of novel therapies Ann. Neurol. 64 Suppl. 2 2008 S16 S29
25. 2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro Eur. J. Neurosci. 27 2008 2501 2514 (Pubitemid 351781658)
26. P.A. LeWitt, and D.C. Taylor Protection against Parkinson's disease progression: clinical experience Neurotherapeutics 5 2008 210 225 (Pubitemid 351446212)
27. L.H. Li, H.Z. Qin, J.L. Wang, J. Wang, X.L. Wang, and G.D. Gao Axonal degeneration of nigra-striatum dopaminergic neurons induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice J. Int. Med. Res. 37 2009 455 463
28. S. Mandel, E. Grunblatt, P. Riederer, M. Gerlach, Y. Levites, and M.B. Youdim Neuroprotective strategies in Parkinson's disease: an update on progress CNS Drugs 17 2003 729 762 (Pubitemid 37000010)
29. M. Martinet, G. Montay, and G. Rhodes Pharmacokinetics and metabolism of riluzole Drugs Today 33 1997 587 594 (Pubitemid 27512563)
30. P.L. McGeer, and E.G. McGeer Glial reactions in Parkinson's disease Mov. Disord. 23 2008 474 483
31. D.G. Nicholls Oxidative stress and energy crises in neuronal dysfunction Ann. N. Y. Acad. Sci. 1147 2008 53 60
32. K.M. Noh, J.Y. Hwang, H.C. Shin, and J.Y. Koh A novel neuroprotective mechanism of riluzole: direct inhibition of protein kinase C Neurobiol. Dis. 7 4 2000 375 383
33. M.C. Obinu, M. Reibaud, V. Blanchard, S. Moussaoui, and A. Imperato Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence Mov. Disord. 17 2002 13 19
34. P.L. Pedersen Transport ATPases into the year 2008: a brief overview related to types, structures, functions and roles in health and disease J. Bioenerg. Biomembr. 39 2007 349 355
35. I.H. Philippens, B.A. 't Hart, and G. Torres The marmoset model of Parkinsonism: a multipurpose non-human primate model for neurodegenerative diseases Drug Discov. Today 15 23-24 Dec 2010 985 990
36. J.H. Song, C.S. Huang, K. Nagata, J.Z. Yeh, and T. Narahashi Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels J. Pharmacol. Exp. Ther. 282 1997 707 714 (Pubitemid 27340171)
37. J. Spiegel, A. Storch, and W.H. Jost Early diagnosis of Parkinson's disease J. Neurol. 253 Suppl. 4 2006 IV2 IV7
38. H. Stephan, G. Baron, and W. Schwerdtfeger The Brain of the Common Marmoset: Callithrix jacchus 1980 Springer Verlag New York
39. A. Storch, K. Burkhardt, A.C. Ludolph, and J. Schwarz Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism J. Neurochem. 75 2000 2259 2269
40. J.M. Stutzmann, M. Lucas, J.C. Blanchard, and P.M. Laduron Riluzole, a glutamate antagonist, enhances slow wave and REM sleep in rats Neurosci. Lett. 88 1988 195 200
41. E. Tolosa, C. Gaig, J. Santamaria, and Y. Compta Diagnosis and the premotor phase of Parkinson disease Neurology 72 2009 S12 S20
42. S.A. van Vliet, M.J. Jongsma, R.A. Vanwersch, B. Olivier, and I.H. Philippens Behavioral effects of modafinil in marmoset monkeys Psychopharmacology (Berl.) 185 2006 433 440
43. P.S. Verhave, R.A. Vanwersch, H.P. van Helden, A.B. Smit, and I.H. Philippens Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease Behav. Brain Res. 200 2009 214 219
44. P.S. Verhave, M.J. Jongsma, R.M. Van den Berg, J.C. Vis, R.A. Vanwersch, A.B. Smit, E.J. Van Someren, and I.H. Philippens REM Sleep Behavior Disorder in the Marmoset MPTP Model of Early Parkinson Disease Sleep 34 8 2011 1119 1125
45. S.J. Wang, K.Y. Wang, and W.C. Wang Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) Neuroscience 125 2004 191 201